ClinicalTrials.gg
CompletedNCT03656718Updated Nov 12, 2025Results posted

A Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20)

A Phase 1/2 interventional study of nivolumab and rHuPH20 in Neoplasms by Site, sponsored by Bristol-Myers Squibb. Completed at 36 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-12.

Sponsored by Bristol-Myers Squibb · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
139
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 119 studies in Neoplasms by Site with a site in United States — 31 open to participants now, 44 under way, 7 of them phase 3. Neoplasms by Site · United States.

Enrollment
44th of 102
139 · median 102
Started
2018
with 5 others
Phase 1/2
23 of 119
9 open now
Registered
61st of 119
by date
Lead sponsor
3 of 119
Bristol-Myers Squibb

Among the 119 studies in Neoplasms by Site with a site in United States, this one is the 44th largest by enrollment of the 102 interventional ones that give a count, is one of 6 that started in 2018, is one of 23 in phase 1/2, and was the 61st registered.

Neoplasms by Site

208 studies on the registry are indexed under Neoplasms by Site; 53 are open to participants now.

Browse Neoplasms by Site studies →

Open to participants now

31 of the 119 studies in Neoplasms by Site with a site in United States are open now. Recruiting first, the newest first:

26 more — sign in →

All 31 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 51 Neoplasms by Site studies recruiting now, 40 (78%) set no upper age limit and 6 (12%) stop at 75 or younger; 7 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 119 studies in Neoplasms by Site with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to investigate the effects of nivolumab when given under the skin with or without rHuPH20.

This study will include participants with 1 of the following advanced or metastatic tumors approved for treatment with nivolumab monotherapy:

  • non-small cell lung cancer (NSCLC)
  • renal cell carcinoma (RCC)
  • unresectable or metastatic melanoma
  • hepatocellular carcinoma (HCC)
  • microsatellite instability-high or mismatch repair deficient colorectal cancer (MSI-H/dMMR CRC)
  • in Part B, other solid tumors may be considered at the discretion of the Clinical Trial Physician
  • In addition to the above tumors, Part E will also include participants with metastatic urothelial carcinoma (mUC).
03

Conditions studied

  • Neoplasms by Site

Browse trials for

Keywords

  • Subcutaneous
  • Nivolumab
  • rHuPH20
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histologic or cytologic confirmation of advanced ( and/or unresectable) solid tumors of one of the following tumor types:

    1. Metastatic squamous or non-squamous NSCLC
    2. RCC, advanced or metastatic
    3. Melanoma
    4. HCC
    5. CRC, metastatic (MSI-H or dMMR)
    6. In Part B, other solid tumor types may be considered at the discretion of the Medical Monitor
    7. In Part E, Metastatic urothelial carcinoma
  • as per version 1.1 criteria
  • performance status of 0 or 1

Exclusion criteria

Exclusion Criteria:

  • Active or
  • Ocular melanoma
  • Active, known, or suspected disease

Other protocol defined inclusion/exclusion criteria apply

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
139 participants (actual)

Study arms

  • Experimental
    Part A, Group 1: nivolumab (dose 1) + rHuPH20

    Biological: nivolumab · Drug: rHuPH20

  • Experimental
    Part B, Group 3: nivolumab (dose 2) + rHuPH20

    Biological: nivolumab · Drug: rHuPH20

  • Experimental
    Part B, Group 2: nivolumab (dose 1)

    Biological: nivolumab

  • Experimental
    Part B, Group 4: nivolumab (dose 2)

    Biological: nivolumab

  • Experimental
    Part C: nivolumab (dose 3) + rHuPH20

    Biological: nivolumab · Drug: rHuPH20

  • Experimental
    Part D, Group 5: nivolumab (dose 3) + rHuPH20

    Biological: nivolumab · Drug: rHuPH20

  • Experimental
    Part E, Group 6: nivolumab (dose 4) coformulated with rHuPH20

    Biological: nivolumab · Drug: rHuPH20

Interventions

  • Biologicalnivolumab

    (Subcutaneous) Specified dose on specified days

    Also known as: Opdivo, BMS-986298

  • Specified dose on specified days Permeation enhancer

    Also known as: ENHANZE™ DP

  • Biologicalnivolumab

    (IV) Specified Dose on Specified Days

    Also known as: BMS-936558

06

What researchers measure

Primary outcomes

  1. Maximum Observed Serum Nivolumab Concentration (Cmax) - Parts A, B, D, and E

    Cmax is the maximum observed serum nivolumab concentration. Collected for Arm A, B, and D on Cycle 1 Day 1, Cycle 1 Day 2, Cycle 1 Day 4, Cycle 1 Day 8, Cycle 1 Day 15, and Cycle 1 Day 21. Collected for Arm E on Cycle 1 Day 1, Cycle 1 Day 2, Cycle 1 Day 4, Cycle 1 Day 8, Cycle 1 Day 15.

    Time frame: From first dose until approximately 21 days post first dose.

  2. Time Taken to Reach Cmax (Tmax) - Parts A, B, D, and E

    Tmax is the time taken to reach the maximum observed serum nivolumab concentration (Cmax). Collected for Arm A, B, and D on Cycle 1 Day 1, Cycle 1 Day 2, Cycle 1 Day 4, Cycle 1 Day 8, Cycle 1 Day 15, and Cycle 1 Day 21. Collected for Arm E on Cycle 1 Day 1, Cycle 1 Day 2, Cycle 1 Day 4, Cycle 1 Day 8, Cycle 1 Day 15.

    Time frame: From first dose until approximately 21 days post first dose.

  3. Area Under the Time-Serum Nivolumab Concentration Curve (AUC (TAU)) - Parts A, B, D, and E

    AUC (TAU) is the area measured under the concentration-time curve taken over the dosing interval. Collected for Arm A, B, and D on Cycle 1 Day 1, Cycle 1 Day 2, Cycle 1 Day 4, Cycle 1 Day 8, Cycle 1 Day 15, and Cycle 1 Day 21. Collected for Arm E on Cycle 1 Day 1, Cycle 1 Day 2, Cycle 1 Day 4, Cycle 1 Day 8, Cycle 1 Day 15.

    Time frame: From first dose until approximately 21 days post first dose.

  4. Observed Serum Nivolumab Concentration at the End of Dosing (Ctau) - Parts A, B, D, and E

    Ctau is the observed serum nivolumab concentration at the end of the dosing interval. Collected for Arma A, B, and D.

    Time frame: At the end of dosing interval of Cycle 1 - first dose (Day 21 for Parts A, B and D; Day 15 for Part E)

  5. Lowest Observed Serum Nivolumab Concentration (Ctrough) During Part C - Part A and B Crossover Participants to Part C

    Ctrough assessed during Part C. Ctrough is the lowest observed serum nivolumab concentration.

    Time frame: On Day 1 of Cycles 2, 3, 5, 9, 13, and 19 of Part C (Day 1 of Part C: up to 14 months from Baseline; each cycle was 28 days)

Secondary outcomes

  1. Number of Participants Experiencing Adverse Events (AEs)

    An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment.

    Time frame: From first dose until 100 days post last dose (up to approximately 70 months).

  2. Number of Participants Experiencing Treatment Related Adverse Events (TRAEs)

    An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment. TRAEs are AEs where a reasonable causal relationship exists between study treatment administration and the AE.

    Time frame: From first dose until 100 days post last dose (up to approximately 70 months).

  3. Number of Participants Experiencing Serious Adverse Events (SAEs)

    A Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose: (a) results in death, (b) is life-threatening (defined as an event in which the participant was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe), and/ or (c) requires inpatient hospitalization or causes prolongation of existing hospitalization.

    Time frame: From first dose until 100 days post last dose (up to approximately 70 months).

  4. Number of Participants Experiencing Treatment Related Serious Adverse Events (TRSAEs)

    A Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose: (a) results in death, (b) is life-threatening (defined as an event in which the participant was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe), and/ or (c) requires inpatient hospitalization or causes prolongation of existing hospitalization. TRSAEs are SAEs where a reasonable causal relationship exists between study treatment administration and the SAE.

    Time frame: From first dose until 100 days post last dose (up to approximately 70 months).

  5. Number of Participants Experiencing Treatment Related Adverse Events (TRAEs) Leading to Discontinuation

    An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment. TRAEs are AEs where a reasonable causal relationship exists between study treatment administration and the AE.

    Time frame: From first dose until 100 days post last dose (up to approximately 70 months).

  6. Number of Participants Who Died

    Number of participants who died due to any cause.

    Time frame: From randomization until data cutoff (up to approximately 70 months).

  7. Number of Participants With Select Laboratory Changes From Baseline

    Laboratory parameters including hematology, chemistry, liver function, and renal function summarized using worst grade NCI CTCAE v.5 criteria. Baseline refers to evaluations with a date on or prior to the day of first dose of study treatment.

    Time frame: From first dose until 30 days post last dose (up to approximately 67 months and 20 days).

  8. Number of Participants Experiencing Any Select Adverse Events Within the Hypersensitivity/Infusion Reaction Category and Broad Standardized MedDRA Query (SMQ) of Anaphylactic Reaction Occurring Within 2 Days of Study Drug Administration

    An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment.

    Time frame: From first dose until 2 days post last dose (up to approximately 66 months and 22 days).

  9. Number of Participants With Anti-Nivolumab Antibodies (ADAs) and Neutralizing Antibodies

    Anti-drug antibody (ADA) Positive: A participant with at least one ADA-positive sample relative to baseline (ADA negative at baseline or ADA titer to be at least 4-fold or greater (\>=) than baseline positive titer) at any time after initiation of treatment; Neutralizing Positive: At least one ADA-positive sample with neutralizing antibodies detected post-baseline. Baseline ADA Positive: A participant with a baseline ADA-positive sample. Baseline refers to evaluations with a date on or prior to the day of first dose of study treatment.

    Time frame: At baseline and up to 100 days post last dose (up to approximately 70 months).

07

Results

Posted Feb 20, 2025

Participant flow

Pre-Treatment Period
Participant flow — Pre-Treatment Period
MilestonePart A - Group 1: Nivolumab + rHuPH20 SC 720mgPart B - Group 2: Nivolumab SC 720mgPart B - Group 3: Nivolumab + rHuPH20 SC 960mgPart B - Group 4: Nivolumab SC 960mgPart C - Nivolumab SC + rHuPH20 1200 mg Q4WPart D: Nivolumab SC + rHuPH20 SC 1200mg Q4WPart E: Nivolumab SC Co-Formulated With rHuPH20 600mg Q2W
Started2218101703636
Completed2218101703636
Not completed0000000
Treatment Period Parts A, B, D, and E
Participant flow — Treatment Period Parts A, B, D, and E
MilestonePart A - Group 1: Nivolumab + rHuPH20 SC 720mgPart B - Group 2: Nivolumab SC 720mgPart B - Group 3: Nivolumab + rHuPH20 SC 960mgPart B - Group 4: Nivolumab SC 960mgPart C - Nivolumab SC + rHuPH20 1200 mg Q4WPart D: Nivolumab SC + rHuPH20 SC 1200mg Q4WPart E: Nivolumab SC Co-Formulated With rHuPH20 600mg Q2W
Started2218101703636
Completed10659076
Not completed12125802930
Withdrew: Disease progression8114602021
Withdrew: Study drug toxicity2112041
Withdrew: Death1000002
Withdrew: Adverse event unrelated to study drug0000041
Withdrew: Participant requested to discontinue study treatment1000002
Withdrew: Other reasons0000013
Treatment Period Part C
Participant flow — Treatment Period Part C
MilestonePart A - Group 1: Nivolumab + rHuPH20 SC 720mgPart B - Group 2: Nivolumab SC 720mgPart B - Group 3: Nivolumab + rHuPH20 SC 960mgPart B - Group 4: Nivolumab SC 960mgPart C - Nivolumab SC + rHuPH20 1200 mg Q4WPart D: Nivolumab SC + rHuPH20 SC 1200mg Q4WPart E: Nivolumab SC Co-Formulated With rHuPH20 600mg Q2W
Started00002800
Completed00001200
Not completed00001600
Withdrew: Disease progression00001200
Withdrew: Death0000100
Withdrew: Participant requested to discontinue study treatment0000100
Withdrew: Other reasons0000100
Withdrew: Maximum clinical benefit0000100

Outcome measures

PrimaryMaximum Observed Serum Nivolumab Concentration (Cmax) - Parts A, B, D, and E

Cmax is the maximum observed serum nivolumab concentration. Collected for Arm A, B, and D on Cycle 1 Day 1, Cycle 1 Day 2, Cycle 1 Day 4, Cycle 1 Day 8, Cycle 1 Day 15, and Cycle 1 Day 21. Collected for Arm E on Cycle 1 Day 1, Cycle 1 Day 2, Cycle 1 Day 4, Cycle 1 Day 8, Cycle 1 Day 15.

Time frame:
From first dose until approximately 21 days post first dose.
Reported as:
Geometric mean · ug/mL
Maximum Observed Serum Nivolumab Concentration (Cmax) - Parts A, B, D, and E
ug/mLPart A - Group 1: Nivolumab + rHuPH20 SC 720mgPart B - Group 2: Nivolumab SC 720mgPart B - Group 3: Nivolumab + rHuPH20 SC 960mgPart B - Group 4: Nivolumab SC 960mgPart D: Nivolumab SC + rHuPH20 SC 1200mg Q4WPart E: Nivolumab SC Co-Formulated With rHuPH20 600mg Q2W
Maximum Observed Serum Nivolumab Concentration (Cmax) - Parts A, B, D, and E54.8 ± 51.056.6 ± 34.081.4 ± 41.063.9 ± 30.0106.0 ± 46.057.8 ± 31.0
PrimaryTime Taken to Reach Cmax (Tmax) - Parts A, B, D, and E

Tmax is the time taken to reach the maximum observed serum nivolumab concentration (Cmax). Collected for Arm A, B, and D on Cycle 1 Day 1, Cycle 1 Day 2, Cycle 1 Day 4, Cycle 1 Day 8, Cycle 1 Day 15, and Cycle 1 Day 21. Collected for Arm E on Cycle 1 Day 1, Cycle 1 Day 2, Cycle 1 Day 4, Cycle 1 Day 8, Cycle 1 Day 15.

Time frame:
From first dose until approximately 21 days post first dose.
Reported as:
Median · hours
Time Taken to Reach Cmax (Tmax) - Parts A, B, D, and E
hoursPart A - Group 1: Nivolumab + rHuPH20 SC 720mgPart B - Group 2: Nivolumab SC 720mgPart B - Group 3: Nivolumab + rHuPH20 SC 960mgPart B - Group 4: Nivolumab SC 960mgPart D: Nivolumab SC + rHuPH20 SC 1200mg Q4WPart E: Nivolumab SC Co-Formulated With rHuPH20 600mg Q2W
Time Taken to Reach Cmax (Tmax) - Parts A, B, D, and E167 (47.0 to 357.0)167 (50.1 to 339.0)141 (47.2 to 333.0)168 (139.0 to 355.0)130 (44.5 to 317.0)130 (45.2 to 337.0)
PrimaryArea Under the Time-Serum Nivolumab Concentration Curve (AUC (TAU)) - Parts A, B, D, and E

AUC (TAU) is the area measured under the concentration-time curve taken over the dosing interval. Collected for Arm A, B, and D on Cycle 1 Day 1, Cycle 1 Day 2, Cycle 1 Day 4, Cycle 1 Day 8, Cycle 1 Day 15, and Cycle 1 Day 21. Collected for Arm E on Cycle 1 Day 1, Cycle 1 Day 2, Cycle 1 Day 4, Cycle 1 Day 8, Cycle 1 Day 15.

Time frame:
From first dose until approximately 21 days post first dose.
Reported as:
Geometric mean · h*ug/mL
Area Under the Time-Serum Nivolumab Concentration Curve (AUC (TAU)) - Parts A, B, D, and E
h*ug/mLPart A - Group 1: Nivolumab + rHuPH20 SC 720mgPart B - Group 2: Nivolumab SC 720mgPart B - Group 3: Nivolumab + rHuPH20 SC 960mgPart B - Group 4: Nivolumab SC 960mgPart D: Nivolumab SC + rHuPH20 SC 1200mg Q4WPart E: Nivolumab SC Co-Formulated With rHuPH20 600mg Q2W
Area Under the Time-Serum Nivolumab Concentration Curve (AUC (TAU)) - Parts A, B, D, and E24908 ± 5327909 ± 3640264 ± 4532702 ± 3153561 ± 4015857 ± 30
PrimaryObserved Serum Nivolumab Concentration at the End of Dosing (Ctau) - Parts A, B, D, and E

Ctau is the observed serum nivolumab concentration at the end of the dosing interval. Collected for Arma A, B, and D.

Time frame:
At the end of dosing interval of Cycle 1 - first dose (Day 21 for Parts A, B and D; Day 15 for Part E)
Reported as:
Geometric mean · ug/mL
Observed Serum Nivolumab Concentration at the End of Dosing (Ctau) - Parts A, B, D, and E
ug/mLPart A - Group 1: Nivolumab + rHuPH20 SC 720mgPart B - Group 2: Nivolumab SC 720mgPart B - Group 3: Nivolumab + rHuPH20 SC 960mgPart B - Group 4: Nivolumab SC 960mgPart D: Nivolumab SC + rHuPH20 SC 1200mg Q4WPart E: Nivolumab SC Co-Formulated With rHuPH20 600mg Q2W
Observed Serum Nivolumab Concentration at the End of Dosing (Ctau) - Parts A, B, D, and E22.2 ± 8626.9 ± 6539.2 ± 6734.8 ± 4154.4 ± 4943.6 ± 36
PrimaryLowest Observed Serum Nivolumab Concentration (Ctrough) During Part C - Part A and B Crossover Participants to Part C

Ctrough assessed during Part C. Ctrough is the lowest observed serum nivolumab concentration.

Time frame:
On Day 1 of Cycles 2, 3, 5, 9, 13, and 19 of Part C (Day 1 of Part C: up to 14 months from Baseline; each cycle was 28 days)
Reported as:
Geometric mean · ug/mL
Lowest Observed Serum Nivolumab Concentration (Ctrough) During Part C - Part A and B Crossover Participants to Part C
ug/mLPart A - Group 1: Nivolumab + rHuPH20 SC 720mgPart B - Group 2: Nivolumab SC 720mgPart B - Group 3: Nivolumab + rHuPH20 SC 960mgPart B - Group 4: Nivolumab SC 960mg
Cycle 2 Day 1115 ± 58106 ± 42124 ± 3885.7 ± 48
Cycle 3 Day 1119 ± 51118 ± 34149 ± 42104 ± 44
Cycle 5 Day 1149 ± 55144 ± 66192 ± 16171 ± 8
Cycle 9 Day 1170 ± 55138 ± 81228 ± NA208 ± 38
Cycle 13 Day 1183 ± 34113 ± 48246 ± NA217 ± 16
Cycle 19 Day 1—74.7 ± NA—212 ± NA
SecondaryNumber of Participants Experiencing Adverse Events (AEs)

An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment.

Time frame:
From first dose until 100 days post last dose (up to approximately 70 months).
Reported as:
Count of participants · Participants
Number of Participants Experiencing Adverse Events (AEs)
ParticipantsPart A - Group 1: Nivolumab + rHuPH20 SC 720mgPart B - Group 2: Nivolumab SC 720mgPart B - Group 3: Nivolumab + rHuPH20 SC 960mgPart B - Group 4: Nivolumab SC 960mgPart C - Nivolumab + rHuPH20 SC 1200mg Q4W (Crossover Participants From Parts A and B)Part D: Nivolumab SC + rHuPH20 SC 1200mg Q4WPart E: Nivolumab SC Co-Formulated With rHuPH20 600mg Q2W
Number of Participants Experiencing Adverse Events (AEs)22181017273636
SecondaryNumber of Participants Experiencing Treatment Related Adverse Events (TRAEs)

An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment. TRAEs are AEs where a reasonable causal relationship exists between study treatment administration and the AE.

Time frame:
From first dose until 100 days post last dose (up to approximately 70 months).
Reported as:
Count of participants · Participants
Number of Participants Experiencing Treatment Related Adverse Events (TRAEs)
ParticipantsPart A - Group 1: Nivolumab + rHuPH20 SC 720mgPart B - Group 2: Nivolumab SC 720mgPart B - Group 3: Nivolumab + rHuPH20 SC 960mgPart B - Group 4: Nivolumab SC 960mgPart C - Nivolumab + rHuPH20 SC 1200mg Q4W (Crossover Participants From Parts A and B)Part D: Nivolumab SC + rHuPH20 SC 1200mg Q4WPart E: Nivolumab SC Co-Formulated With rHuPH20 600mg Q2W
Number of Participants Experiencing Treatment Related Adverse Events (TRAEs)1410811162728
SecondaryNumber of Participants Experiencing Serious Adverse Events (SAEs)

A Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose: (a) results in death, (b) is life-threatening (defined as an event in which the participant was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe), and/ or (c) requires inpatient hospitalization or causes prolongation of existing hospitalization.

Time frame:
From first dose until 100 days post last dose (up to approximately 70 months).
Reported as:
Count of participants · Participants
Number of Participants Experiencing Serious Adverse Events (SAEs)
ParticipantsPart A - Group 1: Nivolumab + rHuPH20 SC 720mgPart B - Group 2: Nivolumab SC 720mgPart B - Group 3: Nivolumab + rHuPH20 SC 960mgPart B - Group 4: Nivolumab SC 960mgPart C - Nivolumab + rHuPH20 SC 1200mg Q4W (Crossover Participants From Parts A and B)Part D: Nivolumab SC + rHuPH20 SC 1200mg Q4WPart E: Nivolumab SC Co-Formulated With rHuPH20 600mg Q2W
Number of Participants Experiencing Serious Adverse Events (SAEs)1210411111925
SecondaryNumber of Participants Experiencing Treatment Related Serious Adverse Events (TRSAEs)

A Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose: (a) results in death, (b) is life-threatening (defined as an event in which the participant was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe), and/ or (c) requires inpatient hospitalization or causes prolongation of existing hospitalization. TRSAEs are SAEs where a reasonable causal relationship exists between study treatment administration and the SAE.

Time frame:
From first dose until 100 days post last dose (up to approximately 70 months).
Reported as:
Count of participants · Participants
Number of Participants Experiencing Treatment Related Serious Adverse Events (TRSAEs)
ParticipantsPart A - Group 1: Nivolumab + rHuPH20 SC 720mgPart B - Group 2: Nivolumab SC 720mgPart B - Group 3: Nivolumab + rHuPH20 SC 960mgPart B - Group 4: Nivolumab SC 960mgPart C - Nivolumab + rHuPH20 SC 1200mg Q4W (Crossover Participants From Parts A and B)Part D: Nivolumab SC + rHuPH20 SC 1200mg Q4WPart E: Nivolumab SC Co-Formulated With rHuPH20 600mg Q2W
Number of Participants Experiencing Treatment Related Serious Adverse Events (TRSAEs)1102031
SecondaryNumber of Participants Experiencing Treatment Related Adverse Events (TRAEs) Leading to Discontinuation

An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment. TRAEs are AEs where a reasonable causal relationship exists between study treatment administration and the AE.

Time frame:
From first dose until 100 days post last dose (up to approximately 70 months).
Reported as:
Count of participants · Participants
Number of Participants Experiencing Treatment Related Adverse Events (TRAEs) Leading to Discontinuation
ParticipantsPart A - Group 1: Nivolumab + rHuPH20 SC 720mgPart B - Group 2: Nivolumab SC 720mgPart B - Group 3: Nivolumab + rHuPH20 SC 960mgPart B - Group 4: Nivolumab SC 960mgPart C - Nivolumab + rHuPH20 SC 1200mg Q4W (Crossover Participants From Parts A and B)Part D: Nivolumab SC + rHuPH20 SC 1200mg Q4WPart E: Nivolumab SC Co-Formulated With rHuPH20 600mg Q2W
Number of Participants Experiencing Treatment Related Adverse Events (TRAEs) Leading to Discontinuation2112042
SecondaryNumber of Participants Who Died

Number of participants who died due to any cause.

Time frame:
From randomization until data cutoff (up to approximately 70 months).
Reported as:
Count of participants · Participants
Number of Participants Who Died
ParticipantsPart A - Group 1: Nivolumab + rHuPH20 SC 720mgPart B - Group 2: Nivolumab SC 720mgPart B - Group 3: Nivolumab + rHuPH20 SC 960mgPart B - Group 4: Nivolumab SC 960mgPart C - Nivolumab + rHuPH20 SC 1200mg Q4W (Crossover Participants From Parts A and B)Part D: Nivolumab SC + rHuPH20 SC 1200mg Q4WPart E: Nivolumab SC Co-Formulated With rHuPH20 600mg Q2W
Number of Participants Who Died1814814172530
SecondaryNumber of Participants With Select Laboratory Changes From Baseline

Laboratory parameters including hematology, chemistry, liver function, and renal function summarized using worst grade NCI CTCAE v.5 criteria. Baseline refers to evaluations with a date on or prior to the day of first dose of study treatment.

Time frame:
From first dose until 30 days post last dose (up to approximately 67 months and 20 days).
Reported as:
Count of participants · Participants
Number of Participants With Select Laboratory Changes From Baseline
ParticipantsPart A - Group 1: Nivolumab + rHuPH20 SC 720mgPart B - Group 2: Nivolumab SC 720mgPart B - Group 3: Nivolumab + rHuPH20 SC 960mgPart B - Group 4: Nivolumab SC 960mgPart C - Nivolumab + rHuPH20 SC 1200mg Q4W (Crossover Participants From Parts A and B)Part D: Nivolumab SC + rHuPH20 SC 1200mg Q4WPart E: Nivolumab SC Co-Formulated With rHuPH20 600mg Q2W
HEMOGLOBIN (g/L)13738151212
PLATELET COUNT (10^9/L)2502564
LEUKOCYTES, LOCAL LAB (10^9/L)1511733
ABSOLUTE NEUTROPHIL COUNT DRV. (10^9/L)2212523
LYMPHOCYTES (ABSOLUTE) (10^9/L)—3—2223
LYMPHOCYTES (ABSOLUTE), LOCAL LAB (10^9/L)1095512716
CREATININE, LOCAL LAB (umol/L)71328812
ALKALINE PHOSPHATASE (ALP) LOCAL LAB (U/L)763981820
ALANINE AMINOTRANSFERASE (ALT), LOCAL LAB (U/L)68379711
ASPARTATE AMINOTRANSFERASE (AST), LOCAL LAB (U/L)594661114
BILIRUBIN, TOTAL, LOCAL LAB (umol/L)2612546
HYPERCALCEMIA (mmol/L)1112263
HYPERKALEMIA (mmol/L)7442979
HYPERMAGNESEMIA (mmol/L)0000000
HYPERNATREMIA (mmol/L)2112543
HYPOCALCEMIA (mmol/L)5222245
HYPOKALEMIA (mmol/L)1111335
HYPOMAGNESEMIA (mmol/L)5113322
HYPONATREMIA (mmol/L)84539913
HYPOGLYCEMIA (mmol/L)1101221
ALBUMIN, LOCAL LAB (g/L)6632—135
ACTIVATED PARTIAL THROMBOPLASTIN TIME (sec)12—1—21
FIBRINOGEN (g/L)00—0—00
SecondaryNumber of Participants Experiencing Any Select Adverse Events Within the Hypersensitivity/Infusion Reaction Category and Broad Standardized MedDRA Query (SMQ) of Anaphylactic Reaction Occurring Within 2 Days of Study Drug Administration

An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment.

Time frame:
From first dose until 2 days post last dose (up to approximately 66 months and 22 days).
Reported as:
Count of participants · Participants
Number of Participants Experiencing Any Select Adverse Events Within the Hypersensitivity/Infusion Reaction Category and Broad Standardized MedDRA Query (SMQ) of Anaphylactic Reaction Occurring Within 2 Days of Study Drug Administration
ParticipantsPart A - Group 1: Nivolumab + rHuPH20 SC 720mgPart B - Group 2: Nivolumab SC 720mgPart B - Group 3: Nivolumab + rHuPH20 SC 960mgPart B - Group 4: Nivolumab SC 960mgPart C - Nivolumab + rHuPH20 SC 1200mg Q4W (Crossover Participants From Parts A and B)Part D: Nivolumab SC + rHuPH20 SC 1200mg Q4WPart E: Nivolumab SC Co-Formulated With rHuPH20 600mg Q2W
Nivolumab administered subcutaneously (SC) +/- rHuPH201100438
Nivolumab administered intravenously (IV)2212———
SecondaryNumber of Participants With Anti-Nivolumab Antibodies (ADAs) and Neutralizing Antibodies

Anti-drug antibody (ADA) Positive: A participant with at least one ADA-positive sample relative to baseline (ADA negative at baseline or ADA titer to be at least 4-fold or greater (\>=) than baseline positive titer) at any time after initiation of treatment; Neutralizing Positive: At least one ADA-positive sample with neutralizing antibodies detected post-baseline. Baseline ADA Positive: A participant with a baseline ADA-positive sample. Baseline refers to evaluations with a date on or prior to the day of first dose of study treatment.

Time frame:
At baseline and up to 100 days post last dose (up to approximately 70 months).
Reported as:
Count of participants · Participants
Number of Participants With Anti-Nivolumab Antibodies (ADAs) and Neutralizing Antibodies
ParticipantsPart A - Group 1: Nivolumab + rHuPH20 SC 720mgPart B - Group 2: Nivolumab SC 720mgPart B - Group 3: Nivolumab + rHuPH20 SC 960mgPart B - Group 4: Nivolumab SC 960mgPart C - Nivolumab + rHuPH20 SC 1200mg Q4W (Crossover Participants From Parts A and B)Part D: Nivolumab SC + rHuPH20 SC 1200mg Q4WPart E: Nivolumab SC Co-Formulated With rHuPH20 600mg Q2W
ANTI-DRUG ANTIBODY (ADA) POSITIVE75307510
NEUTRALIZING POSITIVE0000000
BASELINE ANTI-DRUG ANTIBODY (ADA) POSITIVE2020211

Adverse events

Collected over All-cause Mortality was collected from randomization until the data cutoff date (approximately 70 months). SAEs and Other AEs were collected from the first dose until 100 days post the last dose (up to approximately 70 months).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A - Group 1: Nivolumab + rHuPH20 SC 720mg18/22 (81.8%)12/22 (54.5%)22/22 (100%)
PART A - GRP 1 CROSSOVER to PART C6/9 (66.7%)4/9 (44.4%)9/9 (100%)
Part B - Group 2: Nivolumab SC 720mg14/18 (77.8%)10/18 (55.6%)18/18 (100%)
PART B - GRP 2 CROSSOVER to PART C2/6 (33.3%)1/6 (16.7%)6/6 (100%)
Part B - Group 3: Nivolumab + rHuPH20 SC 960mg8/10 (80%)4/10 (40%)10/10 (100%)
PART B - GRP 3 CROSSOVER to PART C4/5 (80%)2/5 (40%)5/5 (100%)
Part B - Group 4: Nivolumab SC 960mg14/17 (82.4%)11/17 (64.7%)17/17 (100%)
PART B - GRP 4 CROSSOVER to PART C5/8 (62.5%)4/8 (50%)8/8 (100%)
Part D: Nivolumab SC + rHuPH20 SC 1200mg Q4W25/36 (69.4%)19/36 (52.8%)34/36 (94.4%)
Part E: Nivolumab SC Co-Formulated With rHuPH20 600mg Q2W30/36 (83.3%)25/36 (69.4%)35/36 (97.2%)
Most frequent serious events
Showing 10 of 82
Most frequent serious events
EventPart A - Group 1: Nivolumab + rHuPH20 SC 720mgPART A - GRP 1 CROSSOVER to PART CPart B - Group 2: Nivolumab SC 720mgPART B - GRP 2 CROSSOVER to PART CPart B - Group 3: Nivolumab + rHuPH20 SC 960mgPART B - GRP 3 CROSSOVER to PART CPart B - Group 4: Nivolumab SC 960mgPART B - GRP 4 CROSSOVER to PART CPart D: Nivolumab SC + rHuPH20 SC 1200mg Q4WPart E: Nivolumab SC Co-Formulated With rHuPH20 600mg Q2W
PneumoniaInfections and infestations1/220/90/180/62/102/53/172/80/362/36
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)5/221/95/180/60/100/54/171/84/367/36
Infective exacerbation of chronic obstructive airways diseaseInfections and infestations0/220/90/180/61/101/50/170/80/360/36
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders0/220/91/180/61/101/50/170/80/360/36
HypotensionVascular disorders0/220/90/180/61/101/50/170/80/360/36
CholangitisHepatobiliary disorders0/220/92/181/60/100/51/171/80/360/36
CholelithiasisHepatobiliary disorders0/220/91/181/60/100/50/170/80/360/36
Rectal haemorrhageGastrointestinal disorders0/220/90/180/60/100/51/171/80/360/36
Urinary tract infectionInfections and infestations1/220/90/180/60/100/51/171/81/360/36
Cervical vertebral fractureInjury, poisoning and procedural complications0/220/90/180/60/100/51/171/80/360/36
Most frequent other events
Showing 10 of 219
Most frequent other events
EventPart A - Group 1: Nivolumab + rHuPH20 SC 720mgPART A - GRP 1 CROSSOVER to PART CPart B - Group 2: Nivolumab SC 720mgPART B - GRP 2 CROSSOVER to PART CPart B - Group 3: Nivolumab + rHuPH20 SC 960mgPART B - GRP 3 CROSSOVER to PART CPart B - Group 4: Nivolumab SC 960mgPART B - GRP 4 CROSSOVER to PART CPart D: Nivolumab SC + rHuPH20 SC 1200mg Q4WPart E: Nivolumab SC Co-Formulated With rHuPH20 600mg Q2W
Injection site erythemaGeneral disorders4/222/91/181/66/104/52/172/86/361/36
DiarrhoeaGastrointestinal disorders5/222/94/183/61/101/54/172/84/366/36
ArthralgiaMusculoskeletal and connective tissue disorders7/224/92/182/60/100/55/172/85/3610/36
AnaemiaBlood and lymphatic system disorders5/221/96/181/63/102/52/171/83/367/36
AstheniaGeneral disorders5/222/97/182/60/100/52/171/82/368/36
Back painMusculoskeletal and connective tissue disorders4/221/90/180/61/101/53/173/85/365/36
CoughRespiratory, thoracic and mediastinal disorders3/222/91/180/60/100/54/173/83/364/36
HypothyroidismEndocrine disorders2/222/92/182/60/100/51/171/88/368/36
Dry mouthGastrointestinal disorders1/221/93/182/60/100/51/170/80/364/36
VomitingGastrointestinal disorders4/221/92/182/60/100/53/171/83/362/36

Baseline characteristics

Participants in Part C are presented under their original treatment assignment.

Age, Categorical
Age, Categorical(Participants)Part A - Group 1: Nivolumab + rHuPH20 SC 720mgPart B - Group 2: Nivolumab SC 720mgPart B - Group 3: Nivolumab + rHuPH20 SC 960mgPart B - Group 4: Nivolumab SC 960mgPart D: Nivolumab SC + rHuPH20 SC 1200mg Q4WPart E: Nivolumab SC Co-Formulated With rHuPH20 600mg Q2WTotal
<=18 years0000000
Between 18 and 65 years61256141962
>=65 years166511221777
Sex: Female, Male
Sex: Female, Male(Participants)Part A - Group 1: Nivolumab + rHuPH20 SC 720mgPart B - Group 2: Nivolumab SC 720mgPart B - Group 3: Nivolumab + rHuPH20 SC 960mgPart B - Group 4: Nivolumab SC 960mgPart D: Nivolumab SC + rHuPH20 SC 1200mg Q4WPart E: Nivolumab SC Co-Formulated With rHuPH20 600mg Q2WTotal
Female1256510947
Male1013412262792
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part A - Group 1: Nivolumab + rHuPH20 SC 720mgPart B - Group 2: Nivolumab SC 720mgPart B - Group 3: Nivolumab + rHuPH20 SC 960mgPart B - Group 4: Nivolumab SC 960mgPart D: Nivolumab SC + rHuPH20 SC 1200mg Q4WPart E: Nivolumab SC Co-Formulated With rHuPH20 600mg Q2WTotal
Hispanic or Latino1000416
Not Hispanic or Latino4527162256
Unknown or Not Reported1713810161377
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part A - Group 1: Nivolumab + rHuPH20 SC 720mgPart B - Group 2: Nivolumab SC 720mgPart B - Group 3: Nivolumab + rHuPH20 SC 960mgPart B - Group 4: Nivolumab SC 960mgPart D: Nivolumab SC + rHuPH20 SC 1200mg Q4WPart E: Nivolumab SC Co-Formulated With rHuPH20 600mg Q2WTotal
White18188173134126
Black or African American2000103
Other2020318
Not Reported0000000
Asian0000112
08

Study locations

36 sites
  • Winship Cancer Institute.
    Atlanta, Georgia 30322, United States
  • Local Institution - 0024
    Rockville, Maryland 20850, United States
  • Local Institution - 0020
    Detroit, Michigan 48201-2014, United States
  • Local Institution - 0001
    Charlotte, North Carolina 28204, United States
  • Local Institution - 0012
    Eugene, Oregon 97401, United States
  • Greenville Health System
    Greenville, South Carolina 29605, United States
  • Local Institution - 0010
    Austin, Texas 78705, United States
  • Local Institution - 0009
    Beaumont, Texas 77702-1449, United States
  • Local Institution - 0007
    Dallas, Texas 75246, United States
  • Local Institution - 0011
    Tyler, Texas 75702, United States
  • Local Institution - 0035
    CABA, 1199, Argentina
  • Local Institution - 0025
    CABA, 1426, Argentina
  • Local Institution - 0038
    Porto Alegre, Rio Grande do Sul 90610000, Brazil
  • Local Institution - 0037
    São Paulo, 05651-901, Brazil
  • Local Institution - 0005
    Santiago, 0, Chile
  • Local Institution - 0022
    Saint-Herblain, 44805, France
  • Local Institution - 0021
    Villejuif, 94805, France
  • Local Institution - 0003
    Rozzano, MI 20089, Italy
  • Local Institution - 0004
    Padova, 35128, Italy
  • Local Institution - 0050
    Mexico City, Mexico City 03100, Mexico
  • Local Institution - 0048
    Mexico City, Mexico City 14080, Mexico
  • Local Institution - 0046
    Monterrey, Nuevo León 64710, Mexico
  • Local Institution - 0047
    Monterrey, Nuevo León 66460, Mexico
  • Local Institution - 0049
    Puebla City, 72424, Mexico
  • Local Institution - 0045
    Querétaro, 76000, Mexico
  • Local Institution - 0026
    Amsterdam, North Holland 1066 CX, Netherlands
  • Local Institution - 0039
    Maastricht, 6229 HX, Netherlands
  • Local Institution - 0040
    Rotorua, Bay of Plenty 3046, New Zealand
  • Local Institution - 0018
    Newtown, Wellington Region 6021, New Zealand
  • Local Institution - 0014
    Dunedin, 9012, New Zealand
  • Local Institution - 0015
    Tauranga, 3112, New Zealand
  • Local Institution - 0019
    Warsaw, Masovian Voivodeship 02-781, Poland
  • Local Institution - 0017
    Madrid, 28007, Spain
  • Local Institution - 0016
    Málaga, 29010, Spain
  • Local Institution - 0033
    Cardiff, Glamorgan CF14 2TL, United Kingdom
  • Local Institution - 0031
    Liverpool, L7 8YA, United Kingdom
09

References and documents

Publications

  • Lonardi S, Lugowska I, O'Donnell A, Jackson C, Latten-Jansen LM, North R, Bahleda R, Garrido M, Santoro A, Chacon MR, Li L, Joseph D, Vezina HE, Aras U, Bennett B, Perumal D, Gurm B, Ng WT, Harvey RD, Trigo J, Calvo A. Pharmacokinetics and safety of subcutaneous nivolumab: results from the phase I/II CheckMate 8KX study. J Immunother Cancer. 2025 Oct 5;13(10):e011918. doi: 10.1136/jitc-2025-011918. PubMed 41052885 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2018 to primary completion in Sep 2022, 46 months.

Results were first posted in Feb 2025, 2 years 5 months after primary completion. A results delay was requested in Mar 2023.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 28, 2018
First posted
Sep 4, 2018
StartActual
Oct 29, 2018
Primary completionActual
Sep 7, 2022
CompletionActual
Sep 12, 2024
Results delay requested
Mar 15, 2023
Results first posted
Feb 20, 2025
Last update
Nov 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03656718
Responsible party
Sponsor
First posted
Sep 4, 2018
Start date
Oct 29, 2018
Primary completion
Sep 7, 2022
Completion
Sep 12, 2024
Results posted
Feb 20, 2025
Last update
Nov 12, 2025

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nivolumab

Start the discussion